Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Eric Jonasch, M D
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Irvine, California, United States
Charles Nguyen, MDRecruiting - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Recruiting - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting - University of Michigan
Ann Arbor, Michigan, United States
Recruiting - Ut Southwestern Medical Center
Dallas, Texas, United States
Recruiting - M D Anderson Cancer Center
Houston, Texas, United States
Eric Jonasch, M DRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Jan 2024
- Primary completion
- 1 Nov 2026
- Completion
- 1 Nov 2028
- Last update posted
- 20 May 2026
- Registered enrollment
- 48
- Registry id
- NCT06053658
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.